Welcome to our dedicated page for Sigyn Therapeutics news (Ticker: SIGY), a resource for investors and traders seeking the latest updates and insights on Sigyn Therapeutics stock.
Sigyn Therapeutics, Inc. (OTCQB: SIGY) is a San Diego-based innovator developing blood purification technologies to combat life-threatening inflammatory conditions. This page serves as the definitive source for tracking SIGY's progress in advancing Sigyn Therapy™ and its complementary platforms targeting chemotherapy optimization and immunotherapy enhancement.
Investors and medical professionals will find timely updates on clinical milestones, regulatory developments, and strategic initiatives. Key focus areas include first-in-human studies for endotoxemia treatment, advancements in ImmunePrep™ antibody optimization, and progress toward Nasdaq listing requirements through recent corporate restructuring.
Our curated news stream covers essential updates including trial protocol finalizations, technology validation results, partnership announcements, and financial disclosures. All content is vetted for accuracy and relevance to SIGY's mission of addressing unmet needs in sepsis management, cancer care, and infectious disease treatment.
Bookmark this page for streamlined access to SIGY's evolving story in medical technology. Check regularly for developments that could influence both patient outcomes and long-term corporate valuation in this emerging therapeutic sector.
Sigyn Therapeutics (OTCQB: SIGY) has appointed Richa Nand, Jim Dorst, and Christopher Wetzel to its Board of Directors, effective October 10, 2022. This move aims to enhance the company's leadership as it progresses in its clinical development. Nand brings over 20 years of experience in intellectual property law, Dorst has a robust background in finance and operations, while Wetzel holds extensive leadership experience in healthcare delivery. These appointments are expected to bolster Sigyn's strategy in advancing its Sigyn Therapy, which targets pathogen-associated inflammatory disorders.
Sigyn Therapeutics (OTCQB: SIGY) plans to pursue first-in-human feasibility studies of Sigyn Therapy for End-Stage Renal Disease (ESRD) patients experiencing inflammation and endotoxemia. As more than 550,000 individuals in the U.S. suffer from ESRD, and no approved drugs exist for related inflammation, this therapy aims to improve patient outcomes. The therapy combines with regular dialysis to target inflammation by extracting pathogens and cytokines from the bloodstream. The company is updating an Investigational Device Exemption for FDA submission, though success is not guaranteed.
Sigyn Therapeutics, Inc. (OTCQB: SIGY) reported its Q2 2022 financial results, showing a net loss of approximately $666,000, or $0.02 per share. This compares to a net loss of $650,000 in Q2 2021. The company announced the successful completion of in vivo animal studies for its Sigyn Therapy, aimed at treating life-threatening infections and inflammatory disorders. Additionally, it appointed Jeremy Ferrell as CFO and established a Scientific Advisory Board. Sigyn's stock graduated to the OTCQB Venture Exchange, and it continues pursuing a major exchange listing.
Sigyn Therapeutics, Inc. (OTCQB: SIGY) has commenced trading on the OTCQB® Venture Exchange, moving from the OTC Pink Market. This transition aligns with the company's goal of listing on a major exchange. Sigyn Therapeutics is advancing Sigyn Therapy™, a blood purification technology designed to extract infectious pathogens and inflammatory mediators. The technology targets conditions such as sepsis and end-stage renal disease. CEO Jim Joyce emphasized the significance of this development as part of the company's evolution.
Sigyn Therapeutics (OTC: SIGY) has appointed Dr. Donald J. Hillebrand to its Scientific Advisory Board. Dr. Hillebrand is a leading expert in Hepatology and Liver Transplantation. His background includes significant clinical research and contributions to medical literature. Sigyn specializes in treating conditions related to sepsis, utilizing their innovative Sigyn Therapy™ for blood purification that targets pathogen-related inflammation. The company emphasizes the importance of their therapy in addressing severe infectious diseases and liver disorders.
Sigyn Therapeutics, Inc. (OTC Markets: SIGY) announced the appointment of Dr. Ajay Verma to its Scientific Advisory Board. Dr. Verma, a notable figure in neurology, brings extensive clinical experience that is expected to enhance the development of Sigyn Therapy, an extracorporeal blood purification technology aimed at treating life-threatening inflammatory disorders. His previous roles include leading R&D at Yumanity Therapeutics and serving at prominent companies like Biogen and Novartis. Sigyn Therapeutics focuses on addressing sepsis and other severe conditions through innovative medical technology.
Sigyn Therapeutics (OTC: SIGY) has filed its annual report for the year ended December 31, 2021, highlighting significant advancements in its Sigyn Therapy, a blood purification technology aimed at treating sepsis and inflammatory disorders. The company reported an operating loss of approximately $2.0 million, up from $916,000 in 2020. Additionally, it showcased various milestones, including successful studies demonstrating the therapy's effectiveness against viral pathogens and hepatic toxins. Sigyn plans to submit an Investigational Device Exemption to the FDA for clinical studies, indicating a commitment to advancing its innovative treatment.
Sigyn Therapeutics (SIGY) appointed Dr. H. David Humes, a recognized nephrologist, to its Scientific Advisory Board. Dr. Humes brings extensive expertise in medical technology, especially in overseeing preclinical studies of Sigyn Therapy, a blood purification technology aimed at treating sepsis and related conditions. His contributions are expected to enhance clinical advancements for the therapy, which targets life-threatening inflammatory disorders. With a strong academic background and numerous patents, Dr. Humes is well-positioned to support Sigyn's mission to combat sepsis and other serious health threats.
Sigyn Therapeutics, Inc. (OTC Markets: SIGY) has appointed Dr. Alexander S. Yevzlin to its Scientific Advisory Board. Dr. Yevzlin, a leader in Interventional Nephrology, brings extensive experience from his academic and clinical background to advance Sigyn Therapy, a blood purification technology targeting life-threatening inflammatory disorders, including sepsis. His contributions are expected to aid in the clinical advancement of this innovative therapy. Sigyn Therapy aims to address various critical conditions, enhancing the company's focus on significant health challenges.
Sigyn Therapeutics, Inc. (OTC Markets: SIGY) announced the appointment of Jeremy Ferrell, CPA, MBA, as its new Chief Financial Officer, effective March 9, 2022. With over 25 years of finance and operations leadership experience, Ferrell aims to enhance operational finance and manage investor relations. Previously CFO at Miku, Inc., he has notable experience in the life sciences sector. CEO Jim Joyce expressed confidence in Ferrell's ability to support the advancement of Sigyn Therapy and the pursuit of a major exchange listing, highlighting the importance of his role during this transformative period.
FAQ
What is the current stock price of Sigyn Therapeutics (SIGY)?
What is the market cap of Sigyn Therapeutics (SIGY)?
